Asahi Kasei Therapeutics
Corporate Profile
We develop and provide novel therapies centered on the field of orthopedics, as well as critical/intensive care, immunology, urology, and the central nervous system. Through our integrated Japan-U.S. “One AK Pharma” configuration, we are growing as a global specialty pharma company that addresses unmet medical needs and drives the growth of the Asahi Kasei Group.
| Trade name | Asahi Kasei Therapeutics Corp. |
|---|---|
| Main businesses | Pharmaceuticals |
| Home office | Hibiya Mitsui Tower, 1-1-2 Yurakucho, Chiyoda-ku, Tokyo 100-0006 Japan |
| President | Daisuke Okajima |
| Paid-in capital | ¥3,000 million |
| Shareholder | Asahi Kasei Corp. |
| Phone | +81-(0)3-6699-3600 |
(as of April 1, 2026)
Officers
| Yoshikazu Aoki | Chairman & Representative Director |
|---|---|
| Daisuke Okajima | President & Representative Director, Presidential Executive Officer |
| Yasuo Nakamura | Director, Senior Executive Officer |
| Yutaka Osawa | Executive Officer |
| Kazunobu Konishi | Executive Officer |
| Hiroaki Hayashi | Executive Officer |
| Minoru Takada | Corporate Auditor |
(as of April 1, 2026)
Major Subsidiaries and Affiliates
China
| Asahi Kasei Pharma (Beijing) Co., Ltd. | Regulatory affairs and business support in China +86-10-6569-3939 |
|---|